

**UNITED STATES OF AMERICA**  
**Before the**  
**SECURITIES AND EXCHANGE COMMISSION**

**SECURITIES ACT OF 1933**  
**Release No. 9015 / March 9, 2009**

**ADMINISTRATIVE PROCEEDING**  
**File No. 3-13405**

**In the Matter of**

**CANCER DETECTION  
CORPORATION, formerly  
known as Xpention Genetics,  
Inc.,**

**Respondent.**

**ORDER INSTITUTING CEASE-AND-DESIST  
PROCEEDINGS PURSUANT TO SECTION  
8A OF THE SECURITIES ACT OF 1933,  
MAKING FINDINGS, AND IMPOSING A  
CEASE-AND-DESIST ORDER**

**I.**

The Securities and Exchange Commission (“Commission”) deems it appropriate that cease-and-desist proceedings be, and hereby are, instituted pursuant to Section 8A of the Securities Act of 1933 (“Securities Act”), against Cancer Detection Corporation, formerly known as Xpention Genetics, Inc. (“Respondent”). Respondent changed its name to Cancer Detection Corporation in September 2008.

**II.**

In anticipation of the institution of these proceedings, Respondent has submitted an Offer of Settlement (the “Offer”) which the Commission has determined to accept. Solely for the purpose of these proceedings and any other proceedings brought by or on behalf of the Commission, or to which the Commission is a party, and without admitting or denying the findings herein, except as to the Commission’s jurisdiction over it and the subject matter of these proceedings, which are admitted, Respondent consents to the entry of this Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933, Making Findings, and Imposing a Cease-and-Desist Order (“Order”), as set forth below.

**III.**

On the basis of this Order and Respondent’s Offer, the Commission finds that:

1. Respondent is a development stage, Nevada corporation based in Conifer, Colorado. It has licensed a patent related to a tumor-associated “marker” protein known as the p65

marker and funded research related to the marker's correlation with the incidence of cancer in dogs. Respondent is a reporting company pursuant to Section 15(d) of the Securities Exchange Act of 1934. Respondent's common stock is traded over the counter and quoted on the OTC Bulletin Board.

2. These proceedings arise out of a February 2005 reverse merger, involving Respondent, and a coincident failure to comply with the securities registration requirements of Sections 5(a) and 5(c) of the Securities Act. Prior to the merger, Respondent was named Bayview Corporation ("Bayview") and ostensibly operated as an exploration-stage mining company, based in Vancouver, British Columbia, Canada. Bayview's stated plan of operation involved exploration of two Ontario, Canada mineral claims in which Bayview held an option to acquire an ownership interest.

3. In March 2004, Respondent filed a Form SB-2/A amended registration statement with the Commission on behalf of 40 shareholders seeking to resell restricted shares that they had bought directly from Bayview. In its registration statement, Respondent represented that: (1) the described sale of shares by the 40 shareholders would occur without the involvement of underwriters; and (2) Respondent would receive no proceeds from the sale of these shares.

4. In February 2005, Bayview merged with a privately-held biotech startup. This transaction took the form of a reverse merger, with Bayview adopting the biotech startup's business plan and replacing its own management with that of the biotech startup.

5. A stock promotion firm directed the reverse merger as part of an agreement with the biotech startup to take the startup public and raise funds for implementation of its business plan. Contemporaneously, the stock promotion firm and its associates commenced a distribution of the majority of the shares listed in Respondent's registration statement, and Respondent changed its name to Xpention Genetics, Inc. The stock promotion firm and its associates acted as underwriters for the distribution by acquiring the majority of the shares listed in the registration statement and selling such shares to a network of investors, transferring \$400,000 of the proceeds to Respondent in June 2005.

6. The distribution described above violated Respondent's representations in its March 2004 Form SB-2/A and differed materially from the proposed sale of shares that Respondent had registered with the Commission by filing the registration statement. No other registration statements were filed or in effect with respect to the distributed shares, and no exemption from registration applied.

7. Respondent thus participated in, and shared in the proceeds of, an unregistered distribution of its shares. Respondent failed to verify whether the distribution of shares and Respondent's receipt of proceeds complied with representations made by prior management in the March 2004 Form SB-2/A.

8. As a result of the conduct described above, Respondent violated Sections 5(a) and 5(c) of the Securities Act, which prohibit the offer or sale of unregistered securities in interstate commerce unless such securities are offered or sold pursuant to an exemption from registration.

**IV.**

In view of the foregoing, the Commission deems it appropriate to impose the sanctions agreed to in Respondent's Offer.

Accordingly, it is hereby ORDERED that, pursuant to Section 8A of the Securities Act, Respondent cease and desist from committing or causing any violations and any future violations of Sections 5(a) and 5(c) of the Securities Act.

By the Commission.

Elizabeth M. Murphy  
Secretary